
Teva beats on profit, misses on revenue
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today published its first quarter 2025 financial results and revised its 2025 guidance with lower revenue but higher profit. The Israeli pharmaceutical company now expects $16.8-17.2 billion …